Przybojewska B, Rydzynski K, Stepnik M, Jakubiak M, Kozak J, Szymczak W
Department of Toxicology and Carcinogenesis, The Nofer Institute of Occupational Medicine, 90-950 Lodz, Poland.
Neoplasma. 2003;50(3):198-203.
Human non-small-cell lung cancers (NSCLCs) of 48 patients were analyzed immunohistochemically to detect P21 ras and P53 proteins expression. The relationship between P21 ras and P53 proteins expression and clinicopathologic findings was also assessed. DAKO EnVision TM detection system was employed in the study. The P21 ras and P53 proteins expression was shown in 75% (36/48) and 33.3% (16/48) studied NSCLCs, respectively. In both cases the difference was significant when compared with adequate negative control. Simultaneous expression of both studied proteins was observed in all cases in which P53 expression was noticed. No significant association of P21 ras and P53 expression was found with age, histologic type, histologic grade, tumor size or lymph node metastasis of the studied NSCLCs. Therefore, our study suggests that P21 ras and P53 protein play a role in the pathogenesis of NSCLCs but they have no value as a prognostic markers in the case of lung cancers.
对48例人类非小细胞肺癌（NSCLC）进行免疫组织化学分析，以检测P21 ras和P53蛋白的表达。同时评估P21 ras和P53蛋白表达与临床病理结果之间的关系。本研究采用DAKO EnVision TM检测系统。在所研究的NSCLC中，P21 ras和P53蛋白表达分别为75%（36/48）和33.3%（16/48）。与适当的阴性对照相比，这两种情况的差异均具有显著性。在所有发现P53表达的病例中均观察到两种研究蛋白的同时表达。在所研究的NSCLC中，未发现P21 ras和P53表达与年龄、组织学类型、组织学分级、肿瘤大小或淋巴结转移有显著相关性。因此，我们的研究表明，P21 ras和P53蛋白在NSCLC的发病机制中起作用，但在肺癌病例中它们作为预后标志物没有价值。
